Genexine, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-08
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genexine.com
Clinical Trials
53
Active:17
Completed:21
Trial Phases
4 Phases
Phase 1:38
Phase 2:8
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Phase 1
38 (77.6%)Phase 2
8 (16.3%)Phase 3
2 (4.1%)Not Applicable
1 (2.0%)Clinical Trial of Efepoetin Alfa in Healthy Subjects
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06490939
- Locations
- 🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Phase 3
Recruiting
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT06466785
- Locations
- 🇬🇪
Batumi Dialysis and Nephrology Center, Batumi, Georgia
🇬🇪Clinical Center for Nephrology Development, Tbilisi, Georgia
🇬🇪L.Managadze National Center of Urology, Tbilisi, Georgia
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Phase 2
Active, not recruiting
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05191784
- Locations
- 🇰🇷
Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
Phase 2
Withdrawn
- Conditions
- SARS-CoV2 Infection
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Genexine, Inc.
- Registration Number
- NCT05067946
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04915989
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
🇰🇷Gangnam Severance hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found